IAI Announces Medical Assist ELECYLINDER Series

February 1, 2021

Elecylinder, Iai

IAI (Intelligent Actuator Incorporated), a leading robotics provider headquartered in Shizuoka, Japan,­­ would like to introduce their ELECYLINDER®  Series.

Introducing the ELECYLINDER electric actuator developed by IAI. The main features are easy operation, AVD (acceleration / speed / deceleration) that can be adjusted individually, and high performance. Due to its stable quality, it is ideal for the manufacturing industry of medical products where product accuracy is required.

Here is an example of how an ELECYLINDER Series was used to improve a face mask manufacturing process. While using a conventional air cylinder to cut mask connection parts, stoppers gradually worn down. This caused cutting positions to shift, which led to defective products and production had to stop. Implementing the ELECYLINDER eliminated damaged stopper parts, production continued, and productivity got a boost.

“IAI is proud to be in the forefront of technology to assist the medical community in the battle against Covid-19 and any future health crisis,” says Kaz Haruna, National Sales Manager for IAI America. The current pandemic creates an urgent need for readily available multiple testing and diagnostic tools worldwide.

IAI is actively assisting the medical community by providing Cartesian and SCARA robots for infectious disease testing, molecular diagnostics, tissue and blood sampling, genomic research, cancer research, pharmaceuticals, and medical device production. It is IAI’s hope that our ELECYLINDER Series will help the medical/pharmaceutical industries move ahead with advanced innovation.

About IAI: Founded in Shimizu, Japan in 1976, Intelligent Actuator Incorporated (IAI) has over forty years of experience in the design and manufacture of customized medical and industrial robotics. Built on “Quality and Innovation,” IAI is a leader in the research and development of advanced energy-efficient and affordable Cartesian, SCARA, and Tabletop robots. From entry-level to high-speed models, IAI provides complete programmable systems and components to fulfill any and all of your medical testing and industrial production needs.

Iai Map Location

 

 

 

 

 

 

★ USA Headquarters & Western Region
2690 West 237 Street, Torrance, CA 90505
(310) 891-6015

★ Midwest Branch Office
110 East State Parkway, Schaumburg, IL 60173
(847) 908-1400

★ Southern Branch Office
1220 Kennestone Circle, Suite 108
Marietta, GA 30066(678) 354-9470

★ Japan Headquarters
577-1 Obane, Shimizu-ward
Shizuoka-city, Shizuoka-pref.

SourceIAI

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”